溶解

2023年6月16日

Tech.eu Tech.eu見解產生的洞察力和指導策略,其全麵的內容和報告。瀏覽內容流行見解。芬蘭的溶解引起€100萬,與斯坦福大學和合作計劃病原DNA庫抗生素耐藥性的加快識別生物技術創業是解決全球快速抵抗抗生素,資金將燃料的開發和商業化其早期檢測產品芬蘭生物技術啟動溶解在資金籌集了100萬€燃料的開發和商業化的產品計劃建立一個廣泛的病原體DNA庫。抗生素耐藥性是一個主要關注世界範圍內,它已經看到了一些近年來加速。據研究,抗生素耐藥性直接導致全世界2019年,超過一百萬人死亡,近五百萬人死於細菌感染對抗生素耐藥。溶解有宏偉計劃建立一個廣泛的抗生素耐藥性病原體DNA庫,以防止通過更好的研究和更快的識別。病原DNA庫將收集所有病原體實時數據和模型的進化和更有效地識別新health-threatening病原體。“我們使抗藥性細菌的鑒定容易和快速。通常情況下,識別需要時間,但是我們的解決方案,它可以縮短到幾分鍾。實時數據可以有效地檢測細菌和危險的突變,從而能夠盡快阻止其擴散,“溶解的聯合創始人兼首席執行官山姆Sihvonen說,溶解的產品將用於研究抗生素耐藥性在斯坦福大學和漢堡大學。 "Solu allows us to identify antibiotic resistance patterns in our clinical isolates faster and easier than anything we've used before. The ability to quickly and accurately predict patterns of resistance is empowering our research,” says Paul L. Bollyky, Associate Professor at the Department of Medicine at Stanford University Medical Center. The funding round was led by Lifeline Ventures and joined by Wave Ventures. "Significant problems can be solved by bringing new technology bravely into existing industries. Solu combats antibiotic resistance with big data and user-friendliness. The team's courage to tackle a global challenge, along with their ambition and significant partnerships, impressed us. We are excited to support Solu's team early on in developing their ground-breaking solution," says Timo Ahopelto, founding partner of Lifeline Ventures.